Journal of Hematology & Oncology
Journal of Hematology & Oncology | Home page
Research highlights
Journal of Hematology & Oncology is now publishing Research Highlights, commentaries on recently published work that place the new research in the context of the current literature.
Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
Janice Lu
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Jingjing Wu, Jiaping Fu, Mingzhi Zhang, Delong Liu
Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
Gaurav Goel, Weijing Sun
Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
Janice Lu
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Jingjing Wu, Jiaping Fu, Mingzhi Zhang, Delong Liu
Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
Gaurav Goel, Weijing Sun
.png)
No hay comentarios:
Publicar un comentario